Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the government-funded Medicare program.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health condition tied to weight.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 billion proposal from the Biden administration is blessed by President-elect Donald Trump.

Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds.

Use of diabetes and obesity medications such as Ozempic, Wegovy and other so-called GLP-1 drugs has soared among teens and young adults.

Drug regulators in Europe have found no evidence that popular diabetes and weight-loss drugs like Ozempic and Wegovy are linked to a higher risk of suicidal thoughts or actions.

Certain Medicare patients may get help paying for the popular weight-loss drug Wegovy, as long as they also have heart disease.

The popular weight-loss drug Wegovy can now be used to reduce the risk of stroke, heart attacks and other serious heart problems in patients who are overweight or who have obesity.

A new federal study finds that people taking popular diabetes and obesity drugs Ozempic and Wegovy had a lower risk of suicidal thoughts than those taking other medications to treat the same conditions.

Obesity rates in the U.S. have been rising steadily for well over a decade and some of the world’s biggest drug developers are tapping into the growing treatment market.

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients.

A doctor talks about the effects of the wildly popular new drugs and what you should know before and after starting one.

Supply problems and insurance complications have made it difficult for many patients to start and stay on new prescription medications used to treat obesity.

The U.S. Food and Drug Administration is warning consumers not to use versions of the popular weight-loss drug used in Ozempic and Wegovy and sold online because they might not contain the same ingredients as prescription products and may not be safe or effective.

Some compounding pharmacies are using a different form of an active ingredient, semaglutide, that is not approved by the FDA, state regulators say.

A diabetes drug being tested for weight loss is poised to further upend obesity care.

New guidelines suggest children struggling with obesity should be evaluated and treated early and aggressively.

Regulators say a new version of a popular diabetes medicine can be sold as a weight-loss drug in the U.S. The Food and Drug Administration on Friday approved Wegovy.